Cargando…

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation

Objective: We aimed to compare the potential for inducing HIV production and the effect on T-cell activation of potent HDAC inhibitors undergoing clinical investigation. Design: In vitro study Methods: The latently infected cell lines ACH2 and U1 were treated with the HDAC inhibitors panobinostat, g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasmussen, Thomas Aagaard, Søgaard, Ole Schmeltz, Brinkmann, Christel, Wightman, Fiona, Lewin, Sharon R., Melchjorsen, Jesper, Dinarello, Charles, Østergaard, Lars, Tolstrup, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899169/ https://www.ncbi.nlm.nih.gov/pubmed/23370291 http://dx.doi.org/10.4161/hv.23800

Ejemplares similares

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
por: Rasmussen, Thomas A, et al.
Publicado: (2011)

Nanobody‐mediated complement activation to kill HIV‐infected cells
por: Pedersen, Maria Lange, et al.
Publicado: (2023)

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)

The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults
por: Johannesson, Thomas G., et al.
Publicado: (2012)

Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles
por: Kirkegaard, Tea, et al.
Publicado: (2011)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
por: Andersen, Anna Halling Folkmar, et al.
Publicado: (2020)

TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure
por: Hvilsom, Caroline Thue, et al.
Publicado: (2021)

HSV-1-induced chemokine expression via IFI16-dependent and IFI16-independent pathways in human monocyte-derived macrophages
por: Søby, Stine, et al.
Publicado: (2012)

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
por: Winckelmann, Anni, et al.
Publicado: (2017)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis - an observational cohort study
por: Skov Dalgaard, Lars, et al.
Publicado: (2013)

Risk and outcome of pyelonephritis among renal transplant recipients
por: Graversen, Mette Elneff, et al.
Publicado: (2016)

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: author's response
por: Søgaard, Ole Schmeltz
Publicado: (2022)

T Cells Detect Intracellular DNA but Fail to Induce Type I IFN Responses: Implications for Restriction of HIV Replication
por: Berg, Randi K., et al.
Publicado: (2014)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection
por: Barton, Kirston M., et al.
Publicado: (2014)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Risk and Prognosis of Bloodstream Infections among Patients on Chronic Hemodialysis: A Population-Based Cohort Study
por: Skov Dalgaard, Lars, et al.
Publicado: (2015)

Characterization of HIV-1 Infection and Innate Sensing in Different Types of Primary Human Monocyte-Derived Macrophages
por: Diget, Elisabeth A., et al.
Publicado: (2013)

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
por: Denton, Paul W., et al.
Publicado: (2016)

Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy
por: Lu, Hao K., et al.
Publicado: (2014)

Immunomodulation with IL-7 and IL-15 in HIV-1 infection
por: Gunst, Jesper D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f4lvqs1051g6j9aq5j02574f0k